Weekly channel feed

Bio­gen's $7.3B M&A deal, lay­offs; R&D shake­up at Pfiz­er, As­traZeneca; Scal­ing rare dis­ease meds; Q2 earn­ings; and more

Last year

2023 Women in Bio­phar­ma R&D; Biotech hope­ful for re­bound even as new wave of lay­offs hit; No­var­tis' siR­NA buy­out; and more

Last year

Eli Lil­ly’s M&A Fri­day; No­var­tis' TIG­IT breakup; One big hire and one big ex­it; Re­verse merg­er, shut­down and white flags; and more

Last year

Alzheimer’s drug Leqem­bi gets full OK; Biotech’s H1 by the num­bers; Bring­ing Leerink back; Against AI over­hype; and more

3 years ago

Cell ther­a­py for di­a­betes: New da­ta, ap­proval, buy­out; GLP-1 race in weight loss reach­es new stage; FDA fi­nal­ly ap­proves Bio­Marin’s gene ther­a­py; and more

3 years ago

Sarep­ta's Duchenne gene ther­a­py wins OK; FDA spurns NASH drug; Eli Lil­ly buys DICE for $2.4B; The new an­titrust land­scape; and more

3 years ago

Mod­er­na dou­bles down on rare dis­eases; FDA ad­vi­so­ry com­mit­tee votes on fall Covid cam­paign; Il­lu­mi­na CEO steps down; and more

3 years ago

Ad­comm votes yes on Leqem­bi full OK; Mer­ck brings first IRA law­suit; Spe­cial: LGBTQ+ lead­ers; Best-pay­ing bio­phar­ma jobs; and more

3 years ago

Roger Perl­mut­ter lines up deals, fresh fund­ing at Eikon; Sec­ond RSV vac­cine ap­proved; Sev­er­al biotechs flash­ing red; and more

3 years ago

End­points 20(+2) un­der 40, 2023; Bio­phar­ma's high­est-paid CEOs; N-of-1 CRISPR sto­ry goes on af­ter tragedy; and more

3 years ago

FTC’s M&A crack­down; NASH drug gets thumbs down; FDA OKs top­i­cal gene ther­a­py; Com­pa­ny ex­its frus­trate rare dis­ease fam­i­lies; and more

3 years ago

FDA ad­vi­sors back Sarep­ta's gene ther­a­py; Lay­offs, big and small; Gilead, So­bi fu­el M&A fire; End­points 100; and more

3 years ago

Eli Lil­ly's Alzheimer’s win; Astel­las joins buy­er­s' club with $5.9B deal; $540M biotech IPO; His­toric RSV vac­cine OK; and more

3 years ago

M&A vibes amid earn­ings sea­son; CAR-T be­yond can­cer; Lil­ly dou­bles down on obe­si­ty; Two con­se­quen­tial FDA ap­provals; and more

3 years ago

Mer­ck’s $10.8B Prometheus buy­out, GSK’s $2B Bel­lus takeover fu­el M&A buzz; CAR-T da­ta leak; Best of #AACR23; and more

3 years ago

Lat­est on re­ver­ber­a­tions of abor­tion pill rul­ing; Biotech ven­ture fund­ing dips; No­vo Nordisk dives in­to di­a­betes cell ther­a­py; and more

3 years ago

VC trio de­buts seed fund; Take­da cuts ear­ly gene ther­a­py work; Bio­gen’s new face of BD; Biotech in­vestors get hands on; and more

3 years ago

Top 15 bio­phar­ma R&D spenders; The re­turn of Big Car­dio; Math­ai Mam­men takes biotech CEO role; Kris­ten Hege’s next trek; and more

3 years ago

Lat­est on ul­tra-rare dis­ease ap­proval; Pos­i­tive, if mixed, signs for Bio­gen's ALS drug; Clay Sie­gall finds a new job; and more

3 years ago

Seagen goes to Pfiz­er for $43B; Sanofi buys di­a­betes part­ner Proven­tion; Cri­sis avert­ed in SVB demise; and more

3 years ago

Sil­i­con Val­ley Bank shut­ters; Rare dis­ease tri­als can't find enough pa­tients; FDA ad­comm votes in fa­vor of Po­livy la­bel ex­pan­sion; and more

3 years ago

What lat­est wave of lay­offs means for biotech; Ra­dio­ther­a­py short­age; De­liv­er­ing on mR­NA's promis­es; and more

3 years ago

Com­pa­nies flail amid broad biotech fall­out; Sick­le cell reck­on­ing; Fol­low-up on Pfiz­er's CRO trou­ble; and more

3 years ago

Lat­est news on two FDA ap­provals; High-pro­file moves for John Reed, Brent Saun­ders, Christi Shaw..; and more

3 years ago
First page Previous page 2345678 Next page Last page
A service from the Financial Times